For example, the combination of PKM2 activators and LDHA inhibitors significantly reduced cancer growth in a mouse model of pancreatic adenocarcinoma transplantation, suggesting the potential value of multitarget glycolytic inhibitors in combination [232]. Here, PKM is linked to cancer.